Soleno Therapeutics Inc
SLNO
ISIN null / Valor 121339545
Soleno Therapeutics Inc
UMushroom community rating:
About company
Soleno Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative treatments for rare diseases. The company's primary focus is on its lead candidate, DCCR (Diazoxide Choline) Extended-Release tablets, which are designed as a once-daily oral treatment for Prader-Willi syndrome (PWS), a complex genetic disorder. Currently, DCCR is undergoing evaluation in a Phase 3 clinical development program. Soleno aims to address unmet medical needs by providing safe and effective therapeutic solutions that enhance the quality of life for patients with life-threatening rare conditions.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
2732 M
Market cap (USD)
1,472,257
Daily traded volume (Shares)
45.46 / 43.99
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Yiling Guo
Aditya Jain
Meruert Daniyarkyzy
EQUITIES OF THE SAME SECTOR
